immune memory, and antibodies to recall antigens gradually disappear over years. The proportion of allogeneic BMT recipients with Forty-five adult HLA-matched sibling BMT recipients were randomized to receive inactivated poliovirus vacpoliovirus immunity declines during long-term follow-up.
(PV1), poliovirus type 2 (PV2) and poliovirus type 3 (PV3) by a microneutralization assay prior to the first and recently the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation has vaccination, at 6 months after BMT. The corresponding proportion for the late group patients was only 67% at recommended immunization of BMT recipients with IPV. 9 In order to find out if early vaccination of adult allo-18 months. The antibody responses 1 month after each of the three IPV doses were similar in the two vaccigeneic BMT recipients against poliomyelitis is as effective as that given later, a prospective, randomized study with nation groups, except that four-fold responses occurred more frequently after the first dose to PV2 and PV3 in inactivated poliovirus vaccine was carried out, comparing two different vaccination schedules. the late group. All patients had a protective antibody titre to all poliovirus serotypes 1 and 22 months after the third vaccine dose, except one patient in the early group who lacked antibodies to PV3 at 22 months.
Materials and methods Acute GVHD accelerated the decrease of poliovirus antibody titres prior to vaccination but had no influence Patients on vaccination response. Chronic GVHD neither influenced the patient's ability to retain poliovirus antibodies Fifty-five consecutive adults (age у16 years) who had received a bone marrow transplant from a sibling donor prior to vaccination nor impaired responses to vaccinations. A vaccination schedule consisting of three IPV between January 1985 and November 1989 at Helsinki University Central Hospital were randomized into two vaccidoses was equally immunogenic when started at 6 or 18 months after allogeneic BMT.
nation groups at 5 months after transplantation. Informed consent was obtained from the patients before randomizKeywords: inactivated poliovirus vaccine; BMT recipients ation. The vaccination program started either at 6 (early group) or 18 (late group) months after BMT. Eight patients died before the intended vaccinations started (two in the early vaccination group and six in the late group). One Immune reconstitution after allogeneic BMT from cells patient in the early group was treated at another hospital originating from the donor takes 1-2 years in healthy and could not be vaccinated, and one patient in the late recipients and even longer in patients with chronic group relapsed. Characteristics of the remaining 45 patients GVHD.
1,2 The numbers of different lymphocyte types in (23 in the early group and 22 in the late group) are blood involved in immunological functions usually norpresented in Table 1 . malize during the first 6-12 months after BMT. Serum
Patients received a bone marrow graft from an HLAimmunoglobulin levels, except that of IgA, become normal identical, MLC-negative sibling donor. T cell depletion was during the 12-18 months after BMT. 2 However, the connot done. The recipients with haematological malignancy ditioning treatment prior to BMT causes loss of specific were conditioned with cyclophosphamide (60 mg/kg body weight intravenously on 2 consecutive days) and total body irradiation (total dose from 11 to 12 Gy in five or six fractions on 5 consecutive days) or cyclophosphamide and bus- from 41 of the 45 patients before BMT, and from the patients after BMT according to the schedule in Figure 1 .
During the vaccination program and the first year after the third vaccine dose, blood specimens taken within 1 week prior to or 3 weeks after the scheduled time-point were included in the analyses. During the second year after compatient transplanted for aplastic anaemia was conditioned with cyclophosphamide 50 mg/kg on 4 consecutive days pleting the vaccination schedule blood samples taken one month before or after the scheduled time were considered and total nodal irradiation 8.0 Gy in four fractions on 2 consecutive days. Acute GVHD was defined according to adequate. One of the late group patients was vaccinated against polio between 6 and 12 months after BMT. SpeciThomas et al 10 and treated with methylprednisolone, starting with a dose of 2 mg/kg/day or 10-15 mg/kg/day, mens drawn from this patient after vaccination were excluded from the analysis of poliovirus antibodies. depending on the severity of GVHD. Chronic GVHD was defined according to Shulman et al 11 and treated with methylprednisolone alone or in combination with azathioNeutralizing antibodies to poliovirus prine or thalidomide.
The standard microneutralization assay used was based on the standard procedures described by Albrecht et al.
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Vaccination Serum specimens were heat inactivated (30 min at 56°C) and serially diluted on microtitre plates (Nunclon Microtest The 23 patients in the early group were vaccinated at 6, 8 and 14 months and the 22 patients in the late group at 18, 96-well plates). An equal volume of pretitrated virus dilution (corresponding to 100 TCID 50 ) was added, and the 20 and 26 months after BMT with inactivated trivalent poliovirus vaccine (Polio Novum, RIVM, Bilthoven, The plates were sealed. The following virus strains were used: poliovirus type 1 strain Mahoney (PV1), poliovirus type 2 Netherlands) ( Figure 1 ). One 1.0 ml dose of the vaccine contained at least 40-8-32 D-antigen units for poliovirus strain MEF-1 (PV2) and poliovirus type 3 strain Saukett (PV3). After overnight incubation at +36°C, 15 000 Vero types 1, 2 and 3, respectively. The vaccine was administered subcutaneously. Three doses of tetanus toxoid vaccine cells were added per well, and the resealed plates were incubated at 36°C. Virus growth was determined by (manufactured by National Public Health Institute, Helsinki, Finland) were given with the same schedule as the microscopy at 6 days. The highest dilution with complete inhibition of cytopathogenic effect was considered the endpolio vaccine. At the time of the first dose of polio vaccine the patients received Haemophilus influenzae type b polypoint titre. A standard serum preparation, calibrated according to an international reference serum, was included as a saccharide-diphtheria toxoid conjugate vaccine (ProHIBIT; Connaught Laboratories, Swiftwater, PA, USA). At the reference in each assay. For statistical calculations, titres Ͻ4 were given an arbitrary value of 2 and titres Ͼ4096 a time of the second dose of polio vaccine the recipients were immunized with pneumococcal polysaccharide vaccine value of 8192. Poliovirus antibody titres у4 were con-sidered protective. A four-fold or higher increase in antiof the poliovirus antibodies between the groups during the body titre was used as the criterion for response.
22 months after completing the vaccinations (Figure 3 ). The first dose of poliovirus vaccine induced a four-fold or higher increase in antibody titre to PV2 and PV3 in a larger Statistical methods proportion in the late group than in the early group patients Fisher's exact test was used to compare the frequency of (Table 3) . After the subsequent doses, the difference in the individuals in the two vaccination groups with indicated cumulative frequencies of patients with at least a four-fold antibody titres to poliovirus serotypes 1-3 and fold response diminished dose after dose. responses. t-test for two independent samples with logPrior to vaccination, 21 out of 22 early group patients transformed data was used to compare the geometric mean (95%) and 14 out of 21 late group patients (67%) had a titres (GMT) of the poliovirus antibodies between the two poliovirus antibody titre у4 to all three poliovirus serovaccination groups. The paired t-test was used when the types (P = 0.04). At one and 22 months after the third vacGMTs pre-and post-vaccination were compared.
cine dose, all patients had a poliovirus titre у4 to all poliovirus types, except one patient to PV3 in the early group at 22 months. The GMTs measured 6 months after BMT for PV1 and Results PV2 were significantly higher in patients without preceding acute GVHD than in those with it (401 and 434, 78 and Prior to transplantation, the GMTs of the antibodies to 132, respectively; P = 0.003 and P = 0.02, respectively) poliovirus types 1-3 were similar in patients and donors but showed no difference for PV3. The patients without (707 and 1023 for PV1, 1029 and 898 for PV2, and 180 acute GVHD had fewer decreases in antibody titres to PV3 and 318 for PV3, respectively). Forty out of 41 patients than the patients with acute GVHD (a decrease to at least (98%) and all 42 donors with serum samples prior to BMT a quarter of the titre prior to BMT in six out of 18 without had an antibody titre у4 to PV1, all patients and donors vs 18 out of 22 patients with acute GVHD, P = 0.003). to PV2, and 38 patients (93%) and 40 (95%) donors to PV3.
One year after BMT, the GMTs to PV1, PV2 and PV3 in During the first 6 months after BMT the antibody titres the late group patients, not yet vaccinated, were 121, 163 against PV1, PV2 and PV3 continuously decreased (Figure and 42 in those without acute GVHD and 21, 32 and 10 2), at least to a quarter of the titre prior to BMT in 58, 63 in those with acute GVHD (P = 0.03, P = 0.07 and P = and 61% of the patients, respectively. By 18 months after 0.12). Preceding acute GVHD did not impair the vacci-BMT 14 (74%), 15 (79%) and 14 (74%) out of 19 late nation response in either group. group patients showed a decrease to a quarter of the initial Chronic GVHD did not influence patients' ability to antibody titre to PV1, PV2 and PV3, respectively. Prior to retain poliovirus antibodies prior to vaccination or the first vaccinations, the GMTs of the antibodies to PV1, responses to vaccinations. GMTs of the poliovirus anti-PV2 and PV3 were higher in the early group at 6 months bodies at 6 and 10 months after completing the vaccination after BMT than in the late group at 18 months after BMT schedule were similar in patients with and without chronic ( Table 2 ). After each of the three vaccine doses the GMTs GVHD. However, 22 months after the third vaccine dose, were not significantly different in the two vaccination patients in the early group without chronic GVHD had siggroups, although there was a tendency towards higher nificantly or almost significantly higher geometric mean GMTs in the late group for PV2 (P = 0.064) and PV3 (P antibody titres to PV1 (1933 vs 214, P = 0.06), PV2 (1351 = 0.11) after the third vaccine dose. After each vaccination vs 186, P = 0.05) or PV3 (4705 vs 235, P = 0.02) than the GMT was significantly higher than the respective prepatients with chronic GVHD. In the late group this could vaccination titre, except for the second vaccine dose to PV1 not be assessed, as only one patient had chronic GVHD and the first and second vaccine doses to PV2 in the early group. There were no significant differences in the GMTs and serum samples Ͼ36 months after BMT. (21) 402 (15) 330 (20) 1984 (18) 922 (16) 5057 (17) When geometric mean titres between the two groups were compared: a P = 0.0016; 7 Most of the ized with another protein antigen, tetanus toxoid, before BMT recipients whose haematological diagnosis was estab-BMT, the patient has been able to respond to one to two lished only after this campaign and their donors probably doses of the same vaccine during the first year after received oral poliovirus vaccine during the campaign.
BMT. [20] [21] [22] It is possible that the high level of immunity of Those who had their haematological disease diagnosed earlthe present donors against polio is reflected in the better ier were vaccinated with one dose of the new IPV (Polio response rate of the early group compared to other BMT Novum, RIVM) before BMT, as were also their household recipient populations. Thus, even the early group patients, contacts. The recipients had protective antibody levels regardless of their lower general immunologic recovery, against polio prior to BMT. The geometric mean titres were able to respond to the vaccinations. (GMTs) to PV1, PV2 and PV3 were higher among the There is no previous information on the influence of present donors and patients prior to BMT than those among acute GVHD on the ability to retain antibodies to poliovirus the patients pretransplant in the study of Engelhard et al 3 after BMT. In our study the poliovirus antibody titres in tested by a comparable methodology. However, similar propatients with acute GVHD declined earlier compared to portions of the present donors and patients had protective patients without acute GVHD. Vaccination responses were antibody titres prior to BMT to the three poliovirus types similar despite the preceding acute GVHD. Chronic GVHD as the BMT recipients in Sweden 4, 15 and Israel. 3 did not influence vaccination responses. However, approxiAll patients in the early group except one showed protecmately 2 years after the third polio vaccine dose patients tive antibody titres to all three types of polio prior to vacciwith chronic GVHD had lower antibody titres than patients nation at 6 months after BMT, while this was seen only in without. In previous studies with relatively small patient two-thirds of the patients in the late group at 18 months groups, recipients without chronic GVHD either had higher after BMT. In our previous study on poliovirus immunity antibody titres to polio both prior to and after vaccinations 3 using the same methodology, as few as two out of seven or there was no clear influence by chronic GVHD. 4 Chronic BMT recipients were immune to all three poliovirus sero-GVHD has considerable variability in the mode of onset, types at 12 months after BMT. 6 In the study by Ljungman the organ systems involved and the rate of progression.
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et al 4 two-thirds of the patients were seropositive one year In different studies the severity of chronic GVHD and time post-transplantation. interval to vaccinations may be different and explain the In the present study the GMTs of the antibodies to PV1, inconsistent results. PV2 and PV3 were similar in the two vaccination groups
We conclude that polio vaccination should not be postafter each vaccination given at 6, 8 and 14 months or at poned for more than 6 months after BMT. Patients with 18, 20 and 26 months after BMT. The prevaccination chronic GVHD should be vaccinated with the same GMTs were lower in the late than in the early group, as schedule. expected. After the first vaccine dose the fold responses in the antibody titre were greater in the late than in the early group leading to similar post-vaccination GMTs. In spite
